Jan 30, 2025 · View Takeda Pharmaceutical Company Limited's most recent earnings results. Download statements and reports, and listen to earnings announcements.

Dec 31, 2024 · For more details about Takeda’s FY2024 Q3 YTD results, commercial progress, pipeline updates and other financial information, including key assumptions in the FY2024 forecast and management guidance as well as definitions of non-IFRS measures, please refer to Takeda’s FY2024 Q3 investor presentation (available at https://www.takeda.com ...

Feb 1, 2024 · Takeda (TSE:4502/NYSE:TAK ) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). Takeda remains on track towards its full-year Management Guidance at Constant Exchange Rate.

OSAKA, Japan, January 30, 2025 -- (BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024)...

Dec 31, 2024 · Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit …

Jan 30, 2025 · Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025 Results Conference Call January 30, 2025 5:30 AM ETCompany ParticipantsChristopher O’Reilly - Head,...

Feb 1, 2024 · With year-to-date strong momentum in its Growth & Launch Products (+12.7% at CER) offsetting the significant revenue impact of generic entrants, Takeda remains on track towards its full-year...

Jan 30, 2025 · Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Jan 30, 2025 · Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year profit outlook.

Jan 30, 2025 · These announcements came as Takeda reported its Q3, 2024 earnings, which buoyed interest from analysts. Overall sales for the quarter beat consensus by 5.1%. Jefferies noted that sales of off-patent ADHD treatment Vyvanse were stronger than expected, offsetting weak sales of irritable bowel treatment Entyvio.